Trial Profile
A Retrospective Study Assessing the Efficacy and Tolerability of Single agent Trabected in Heavily Pretreated Patients with Recurrent Ovarian Cancer (ROC)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Aug 2017
Price :
$35
*
At a glance
- Drugs Trabectedin (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- 12 Jul 2017 Results published in the Gynecologic Oncology Journal.
- 21 Jul 2015 New trial record